function confirmModerate(url,num,pid){ url = url + '?Comments[do]=mod&Comments[pid]=' + pid + '&Comments[id]=' + num + '#Comments_' + num; if (confirm('Do you want to report this comment as inappropriate?')) location.href=url; return 0; } function validate_form(frm) { var value = ''; var errFlag = new Array(); _qfMsg = ''; value = frm.elements['Comments[name]'].value; if (value == '' && !errFlag['name']) { errFlag['name'] = true; _qfMsg = _qfMsg + '\n - Please enter your name'; } value = frm.elements['Comments[captcha]'].value; if (value == '' && !errFlag['captcha']) { errFlag['captcha'] = true; _qfMsg = _qfMsg + '\n - Please enter Security Code'; } value = frm.elements['Comments[mail]'].value; if (value == '' && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - Please enter your e-mail'; } var regex = /^((\"[^\"\f\n\r\t\v\b]+\")|([\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+(\.[\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+)*))@((\[(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))\])|(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))|((([A-Za-z0-9\-])+\.)+[A-Za-z\-]+))$/; if (value != '' &&!regex.test(value) && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - E-mail address format is invalid'; } value = frm.elements['Comments[text]'].value; if (value == '' && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Please enter your comment'; } if (value.length<50 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too short (50 characters min.)'; } if (value.length>4000 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too long (4000 characters max)'; } if (_qfMsg != '') { _qfMsg = 'Invalid information entered:' + _qfMsg + '\nPlease correct these fields.'; alert(_qfMsg); return false; } return true; } //]]>

Exelixis, Inc

Article Abstract:

A comparative analysis of the company sales and financial details of Exelixis, Inc. from 1998 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.

Author: Kuboyama, C.F.

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004

United States, Sales, profits & dividends, Company sales and earnings, Company earnings/profit

User Contributions:

Comment about this article or add new information about this topic:

Exelixis, Inc

Article Abstract:

The price appreciation potential of Exelixis, Corp. for the years 2010-2012 is discussed. The San Francisco, California-based company develops drugs through comparative and model system genomics.

Author: Rho, George

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007

Evaluation, Stocks, Stock prices

User Contributions:

Comment about this article or add new information about this topic:

Subjects list: United States, Biotechnology industry, Biotechnology industries, Securities, Exelixis Inc., Company securities

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.